Opelz G
Department of Transplantation Immunology, University of Heidelberg, Germany.
Transplantation. 1994 Aug 27;58(4):443-6. doi: 10.1097/00007890-199408270-00009.
Renal transplant recipients require long-term maintenance immunosuppression for prevention of graft rejection. To reduce harmful side effects, combinations of immunosuppressive drugs are used. The effect on long-term outcome of different drug regimen has not been established. Over 12,000 kidney recipients who initially received triple-drug immunosuppressive therapy (cyclosporine, steroids, and azathioprine) after transplantation were studied. Graft and patient survival rates were analyzed over a 5-year period in relation to the 1-year immunosuppressive regimen. Five-year graft survival was significantly higher in 1270 patients who were changed from triple-drug therapy to steroid-free maintenance with cyclosporine (with or without the addition of azathioprine) (87 +/- 1%) than in 8024 patients who remained on triple-drug therapy (76 +/- 1%, P < 0.0001), 2829 patients on cyclosporine and steroids (79 +/- 1%, P < 0.0001), and 830 patients on steroids and azathioprine (63 +/- 2%, P < 0.0001). Patient survival was also significantly higher in patients on steroid-free maintenance (P < 0.0001). Steroid-free patients received significantly higher doses of cyclosporine than patients on regimens containing steroids (P < 0.0001). The immunosuppressive maintenance protocols that are currently most widely used appear to give suboptimal results. We suggest that discontinuation of steroid therapy should be attempted in renal transplant recipients after they have experienced several months of stable graft function on triple-drug immunosuppression.
肾移植受者需要长期维持免疫抑制治疗以预防移植物排斥反应。为减少有害副作用,常联合使用免疫抑制药物。不同药物方案对长期预后的影响尚未明确。研究了12000多名肾移植受者,这些受者在移植后最初接受三联药物免疫抑制治疗(环孢素、类固醇和硫唑嘌呤)。在5年期间,根据1年的免疫抑制方案分析移植物和患者生存率。1270名从三联药物治疗改为使用环孢素(加或不加硫唑嘌呤)的无类固醇维持治疗的患者,其5年移植物生存率(87±1%)显著高于8024名继续接受三联药物治疗的患者(76±1%,P<0.0001)、2829名接受环孢素和类固醇治疗的患者(79±1%,P<0.0001)以及830名接受类固醇和硫唑嘌呤治疗的患者(63±2%,P<0.0001)。无类固醇维持治疗患者的患者生存率也显著更高(P<0.0001)。无类固醇患者接受的环孢素剂量显著高于含类固醇方案的患者(P<0.0001)。目前最广泛使用的免疫抑制维持方案似乎效果欠佳。我们建议,肾移植受者在三联药物免疫抑制治疗下经历数月移植物功能稳定后,应尝试停用类固醇治疗。